Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia
- 482 Downloads
Standard myeloablative conditioning regimens for children with acute lymphoblastic leukaemia are based on total body irradiation (TBI). However, TBI causes profound short-term and long-term side effects, provoking the necessity for alternative regimens. Treosulfan combines a potent immunosuppressive and antileukaemic effect with myeloablative activity and low toxicity profile. We retrospectively studied toxicity and outcome of 71 paediatric patients with acute lymphoblastic leukaemia (ALL) undergoing haematopoietic stem cell transplantation (HSCT) following treosulfan-based conditioning aiming to identify risk factors for treatment failure and dose-depending outcome differences. Early regimen-related toxicity was low. No case of veno-occlusive disease was reported. There was no association of toxicity with age or number of HSCT. Event-free survival (EFS) of infants was significantly better compared to older children. Overall survival (OS) at 3 years was 51 % and not significantly influenced by number of HSCT (first HSCT 54 %, ≥second HSCT 44 %, p = 0.71). In multivariate analysis, OS and EFS were significantly worse for patients transplanted without complete remission (p = 0.04 and 0.004). Treatment-related mortality was low at 14 %. We conclude that treosulfan-based conditioning is a safe and efficacious approach for paediatric ALL.
KeywordsTreosulfan ALL Paediatrics Stem cell transplantation Toxicity
We thank Arnaud Dalassier for data correction and management.
Conflict of interest
The EBMT received an unrestricted grant for the retrospective data collection and analysis from medac GmbH. CP received travel grants and study support from medac, Pierre Fabre, Sanofi and Novartis. HB received a travel grant from Pierre Fabre. KWS received travel grants and study support from medac.
- 4.Eckert C, Henze G, Seeger K et al (2013) Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group. J Clin Oncol 31:2736–2742PubMedCrossRefGoogle Scholar
- 6.Balduzzi A, Valsecchi MG, Uderzo C et al (2005) Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study. Lancet 366:635–642PubMedCrossRefGoogle Scholar
- 11.Marks DI, Forman SJ, Blume KG et al (2006) A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. Biol Blood Marrow Transplant 12:438–453PubMedCrossRefGoogle Scholar
- 15.Bunin N, Aplenc R, Kamani N, Shaw K, Cnaan A, Simms S (2003) Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a pediatric blood and marrow transplant consortium study. Bone Marrow Transplant 32:543–548PubMedCrossRefGoogle Scholar
- 21.van Pel M, van Breugel DW, Vos W, Ploemacher RE, Boog CJ (2003) Towards a myeloablative regimen with clinical potential: I. Treosulfan conditioning and bone marrow transplantation allow induction of donor-specific tolerance for skin grafts across full MHC barriers. Bone Marrow Transplant 32:15–22PubMedCrossRefGoogle Scholar
- 22.Poetschger U, Sykora K-W, Zecca M et al (2012) Meta-analysis on treosulfan for conditioning in children and adolescents before hematopoietic stem cell transplantation. Bone Marrow Transplant 47:S37Google Scholar
- 29.Levy JM. Tello T. Giller R. et al. Late effects of total body irradiation and hematopoietic stem cell transplant in children under 3 years of age. Pediatr Blood Cancer 2012.Google Scholar
- 35.Ansari M. Theoret Y. Rezgui MA. et al. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation. Ther Drug Monit 2013Google Scholar
- 45.Law J, Cowan MJ, Dvorak CC et al (2012) Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution. Biol Blood Marrow Transplant 18:1656–1663PubMedCrossRefGoogle Scholar
- 50.Bartelink IH. van Reij EM. Gerhardt CE. et al. Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity. Biol Blood Marrow Transplant 2013.Google Scholar
- 52.Mann G, Attarbaschi A, Schrappe M et al (2010) Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study. Blood 116:2644–2650PubMedCrossRefGoogle Scholar